LV10972B - Erythropoietin analogs - Google Patents

Erythropoietin analogs Download PDF

Info

Publication number: LV10972B
Authority: LV; Latvia
Prior art keywords: epo; erythropoietin; analogue; isoforms; ser
Prior art date: 1993-08-17

Application number

LVP-95-99A

Other languages

English (en)

Latvian (lv)

Other versions

LV10972A (lv

Inventor

Steven G Elliott

Thomas E Byrne

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-08-17

Filing date

1995-04-17

Publication date

1996-10-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22319789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LV10972(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-04-17 Application filed by Amgen Inc filed Critical Amgen Inc

1995-12-20 Publication of LV10972A publication Critical patent/LV10972A/xx

1996-10-20 Publication of LV10972B publication Critical patent/LV10972B/en

Links

OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical class [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title claims description 352
101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 claims abstract description 84
102000044890 human EPO Human genes 0.000 claims abstract description 84
101000920686 Homo sapiens Erythropoietin Proteins 0.000 claims abstract description 80
238000006206 glycosylation reaction Methods 0.000 claims abstract description 51
230000013595 glycosylation Effects 0.000 claims abstract description 45
108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 17
230000008707 rearrangement Effects 0.000 claims abstract description 12
108090000394 Erythropoietin Proteins 0.000 claims description 312
102000003951 Erythropoietin Human genes 0.000 claims description 309
229940105423 erythropoietin Drugs 0.000 claims description 296
239000000203 mixture Substances 0.000 claims description 50
150000001720 carbohydrates Chemical class 0.000 claims description 49
150000001413 amino acids Chemical group 0.000 claims description 27
235000001014 amino acid Nutrition 0.000 claims description 23
229940024606 amino acid Drugs 0.000 claims description 21
102000011022 Chorionic Gonadotropin Human genes 0.000 claims description 15
108010062540 Chorionic Gonadotropin Proteins 0.000 claims description 15
229940084986 human chorionic gonadotropin Drugs 0.000 claims description 13
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 12
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 8
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 6
108091029865 Exogenous DNA Proteins 0.000 claims description 5
125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims description 5
238000012217 deletion Methods 0.000 claims description 5
230000037430 deletion Effects 0.000 claims description 5
239000003085 diluting agent Substances 0.000 claims description 5
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 4
239000004473 Threonine Substances 0.000 claims description 4
102000007079 Peptide Fragments Human genes 0.000 claims description 2
108010033276 Peptide Fragments Proteins 0.000 claims description 2
108010092408 Eosinophil Peroxidase Proteins 0.000 claims 22
102100031939 Erythropoietin Human genes 0.000 claims 22
125000000837 carbohydrate group Chemical group 0.000 claims 8
150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
108020004414 DNA Proteins 0.000 abstract description 28
102000001708 Protein Isoforms Human genes 0.000 description 237
108010029485 Protein Isoforms Proteins 0.000 description 237
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 72
230000000694 effects Effects 0.000 description 57
238000000034 method Methods 0.000 description 49
239000000499 gel Substances 0.000 description 48
238000001155 isoelectric focusing Methods 0.000 description 46
239000012634 fragment Substances 0.000 description 41
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 38
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 38
239000002299 complementary DNA Substances 0.000 description 36
238000001727 in vivo Methods 0.000 description 36
238000002360 preparation method Methods 0.000 description 35
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 34
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 33
239000000872 buffer Substances 0.000 description 32
108090000623 proteins and genes Proteins 0.000 description 31
125000005629 sialic acid group Chemical group 0.000 description 30
239000007983 Tris buffer Substances 0.000 description 27
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 27
108020004707 nucleic acids Proteins 0.000 description 24
102000039446 nucleic acids Human genes 0.000 description 24
150000007523 nucleic acids Chemical class 0.000 description 24
-1 N21 Chemical compound 0.000 description 23
239000013612 plasmid Substances 0.000 description 23
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 22
102000004169 proteins and genes Human genes 0.000 description 22
125000003275 alpha amino acid group Chemical group 0.000 description 21
235000018102 proteins Nutrition 0.000 description 21
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 19
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
238000003556 assay Methods 0.000 description 18
238000007792 addition Methods 0.000 description 17
239000004202 carbamide Substances 0.000 description 17
235000014633 carbohydrates Nutrition 0.000 description 17
239000006228 supernatant Substances 0.000 description 17
238000003127 radioimmunoassay Methods 0.000 description 16
239000011780 sodium chloride Substances 0.000 description 16
230000035772 mutation Effects 0.000 description 15
150000002482 oligosaccharides Polymers 0.000 description 15
230000004071 biological effect Effects 0.000 description 14
238000005534 hematocrit Methods 0.000 description 14
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 13
238000000338 in vitro Methods 0.000 description 13
239000002609 medium Substances 0.000 description 13
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
239000004471 Glycine Substances 0.000 description 11
238000004587 chromatography analysis Methods 0.000 description 11
229910000366 copper(II) sulfate Inorganic materials 0.000 description 11
238000002703 mutagenesis Methods 0.000 description 11
231100000350 mutagenesis Toxicity 0.000 description 11
108090000765 processed proteins & peptides Proteins 0.000 description 11
239000000243 solution Substances 0.000 description 11
230000002485 urinary effect Effects 0.000 description 11
241000699666 Mus <mouse, genus> Species 0.000 description 10
230000004988 N-glycosylation Effects 0.000 description 10
239000012614 Q-Sepharose Substances 0.000 description 10
238000002835 absorbance Methods 0.000 description 10
238000004458 analytical method Methods 0.000 description 10
239000000523 sample Substances 0.000 description 10
239000007858 starting material Substances 0.000 description 10
238000006467 substitution reaction Methods 0.000 description 10
239000013598 vector Substances 0.000 description 10
238000009010 Bradford assay Methods 0.000 description 9
102000003886 Glycoproteins Human genes 0.000 description 9
108090000288 Glycoproteins Proteins 0.000 description 9
238000010276 construction Methods 0.000 description 9
230000004048 modification Effects 0.000 description 9
238000012986 modification Methods 0.000 description 9
239000011347 resin Substances 0.000 description 9
229920005989 resin Polymers 0.000 description 9
102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 8
108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 8
230000029087 digestion Effects 0.000 description 8
229920001542 oligosaccharide Polymers 0.000 description 8
229910001868 water Inorganic materials 0.000 description 8
239000012564 Q sepharose fast flow resin Substances 0.000 description 7
239000002253 acid Substances 0.000 description 7
238000004166 bioassay Methods 0.000 description 7
210000004369 blood Anatomy 0.000 description 7
239000008280 blood Substances 0.000 description 7
239000003636 conditioned culture medium Substances 0.000 description 7
230000003247 decreasing effect Effects 0.000 description 7
239000013615 primer Substances 0.000 description 7
108020003175 receptors Proteins 0.000 description 7
102000005962 receptors Human genes 0.000 description 7
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
241000699670 Mus sp. Species 0.000 description 6
230000002378 acidificating effect Effects 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
229930182830 galactose Natural products 0.000 description 6
238000005342 ion exchange Methods 0.000 description 6
238000004255 ion exchange chromatography Methods 0.000 description 6
229920001184 polypeptide Polymers 0.000 description 6
102000004196 processed proteins & peptides Human genes 0.000 description 6
239000000047 product Substances 0.000 description 6
238000000746 purification Methods 0.000 description 6
210000002966 serum Anatomy 0.000 description 6
239000002002 slurry Substances 0.000 description 6
238000001262 western blot Methods 0.000 description 6
108091034117 Oligonucleotide Proteins 0.000 description 5
210000004899 c-terminal region Anatomy 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
229920000936 Agarose Polymers 0.000 description 4
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 4
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 4
239000003155 DNA primer Substances 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
241000473945 Theria <moth genus> Species 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
229960001230 asparagine Drugs 0.000 description 4
235000009582 asparagine Nutrition 0.000 description 4
238000011098 chromatofocusing Methods 0.000 description 4
230000000875 corresponding effect Effects 0.000 description 4
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
238000009826 distribution Methods 0.000 description 4
230000000925 erythroid effect Effects 0.000 description 4
230000004927 fusion Effects 0.000 description 4
238000009396 hybridization Methods 0.000 description 4
238000002955 isolation Methods 0.000 description 4
230000005012 migration Effects 0.000 description 4
238000013508 migration Methods 0.000 description 4
230000036961 partial effect Effects 0.000 description 4
239000002953 phosphate buffered saline Substances 0.000 description 4
230000000581 polycythemic effect Effects 0.000 description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
238000000926 separation method Methods 0.000 description 4
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 4
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 4
238000000108 ultra-filtration Methods 0.000 description 4
ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
102000053602 DNA Human genes 0.000 description 3
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
108010075944 Erythropoietin Receptors Proteins 0.000 description 3
102100036509 Erythropoietin receptor Human genes 0.000 description 3
241000700159 Rattus Species 0.000 description 3
229920002684 Sepharose Polymers 0.000 description 3
108020004682 Single-Stranded DNA Proteins 0.000 description 3
108010022394 Threonine synthase Proteins 0.000 description 3
125000000539 amino acid group Chemical group 0.000 description 3
208000007502 anemia Diseases 0.000 description 3
108010064886 beta-D-galactoside alpha 2-6-sialyltransferase Proteins 0.000 description 3
238000004364 calculation method Methods 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
238000010367 cloning Methods 0.000 description 3
102000004419 dihydrofolate reductase Human genes 0.000 description 3
238000004520 electroporation Methods 0.000 description 3
238000001641 gel filtration chromatography Methods 0.000 description 3
108010057821 leucylproline Proteins 0.000 description 3
239000007791 liquid phase Substances 0.000 description 3
238000005259 measurement Methods 0.000 description 3
239000012528 membrane Substances 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
239000012071 phase Substances 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
238000004366 reverse phase liquid chromatography Methods 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
210000002700 urine Anatomy 0.000 description 3
238000005406 washing Methods 0.000 description 3
UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
241000699802 Cricetulus griseus Species 0.000 description 2
102000004594 DNA Polymerase I Human genes 0.000 description 2
108010017826 DNA Polymerase I Proteins 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
KSZCCRIGNVSHFH-UWVGGRQHSA-N Leu-Arg-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O KSZCCRIGNVSHFH-UWVGGRQHSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 2
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 2
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
108010071390 Serum Albumin Proteins 0.000 description 2
102000007562 Serum Albumin Human genes 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
235000004279 alanine Nutrition 0.000 description 2
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
108010005233 alanylglutamic acid Proteins 0.000 description 2
108010087924 alanylproline Proteins 0.000 description 2
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
230000008033 biological extinction Effects 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
230000008859 change Effects 0.000 description 2
230000001332 colony forming effect Effects 0.000 description 2
230000002950 deficient Effects 0.000 description 2
DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
238000006073 displacement reaction Methods 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
108010077515 glycylproline Proteins 0.000 description 2
238000012872 hydroxylapatite chromatography Methods 0.000 description 2
238000005462 in vivo assay Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
108010009298 lysylglutamic acid Proteins 0.000 description 2
239000000463 material Substances 0.000 description 2
238000007747 plating Methods 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
108010077112 prolyl-proline Proteins 0.000 description 2
238000001525 receptor binding assay Methods 0.000 description 2
238000004007 reversed phase HPLC Methods 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
108010026333 seryl-proline Proteins 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000001509 sodium citrate Substances 0.000 description 2
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
239000002904 solvent Substances 0.000 description 2
YUXKOWPNKJSTPQ-AXWWPMSFSA-N (2s,3r)-2-amino-3-hydroxybutanoic acid;(2s)-2-amino-3-hydroxypropanoic acid Chemical compound OC[C@H](N)C(O)=O.C[C@@H](O)[C@H](N)C(O)=O YUXKOWPNKJSTPQ-AXWWPMSFSA-N 0.000 description 1
YRIZYWQGELRKNT-UHFFFAOYSA-N 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione Chemical compound ClN1C(=O)N(Cl)C(=O)N(Cl)C1=O YRIZYWQGELRKNT-UHFFFAOYSA-N 0.000 description 1
BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 1
WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
AWAXZRDKUHOPBO-GUBZILKMSA-N Ala-Gln-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O AWAXZRDKUHOPBO-GUBZILKMSA-N 0.000 description 1
VNYMOTCMNHJGTG-JBDRJPRFSA-N Ala-Ile-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O VNYMOTCMNHJGTG-JBDRJPRFSA-N 0.000 description 1
MNZHHDPWDWQJCQ-YUMQZZPRSA-N Ala-Leu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O MNZHHDPWDWQJCQ-YUMQZZPRSA-N 0.000 description 1
OLVCTPPSXNRGKV-GUBZILKMSA-N Ala-Pro-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 OLVCTPPSXNRGKV-GUBZILKMSA-N 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
208000032467 Aplastic anaemia Diseases 0.000 description 1
CGWVCWFQGXOUSJ-ULQDDVLXSA-N Arg-Tyr-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O CGWVCWFQGXOUSJ-ULQDDVLXSA-N 0.000 description 1
108010002913 Asialoglycoproteins Proteins 0.000 description 1
DJIMLSXHXKWADV-CIUDSAMLSA-N Asn-Leu-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(N)=O DJIMLSXHXKWADV-CIUDSAMLSA-N 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
0 CC1=C**CC1 Chemical compound CC1=C**CC1 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
GGRDJANMZPGMNS-CIUDSAMLSA-N Cys-Ser-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O GGRDJANMZPGMNS-CIUDSAMLSA-N 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000011891 EIA kit Methods 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
208000036566 Erythroleukaemia Diseases 0.000 description 1
FGWRYRAVBVOHIB-XIRDDKMYSA-N Gln-Pro-Trp Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CCC(=O)N)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O FGWRYRAVBVOHIB-XIRDDKMYSA-N 0.000 description 1
UTKICHUQEQBDGC-ACZMJKKPSA-N Glu-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)O)N UTKICHUQEQBDGC-ACZMJKKPSA-N 0.000 description 1
SYWCGQOIIARSIX-SRVKXCTJSA-N Glu-Pro-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O SYWCGQOIIARSIX-SRVKXCTJSA-N 0.000 description 1
SCCPDJAQCXWPTF-VKHMYHEASA-N Gly-Asp Chemical compound NCC(=O)N[C@H](C(O)=O)CC(O)=O SCCPDJAQCXWPTF-VKHMYHEASA-N 0.000 description 1
XLFHCWHXKSFVIB-BQBZGAKWSA-N Gly-Gln-Gln Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O XLFHCWHXKSFVIB-BQBZGAKWSA-N 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
PMMMQRVUMVURGJ-XUXIUFHCSA-N Ile-Leu-Pro Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(O)=O PMMMQRVUMVURGJ-XUXIUFHCSA-N 0.000 description 1
DRCKHKZYDLJYFQ-YWIQKCBGSA-N Ile-Thr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DRCKHKZYDLJYFQ-YWIQKCBGSA-N 0.000 description 1
NURNJECQNNCRBK-FLBSBUHZSA-N Ile-Thr-Thr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NURNJECQNNCRBK-FLBSBUHZSA-N 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
UCOCBWDBHCUPQP-DCAQKATOSA-N Leu-Arg-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O UCOCBWDBHCUPQP-DCAQKATOSA-N 0.000 description 1
NFNVDJGXRFEYTK-YUMQZZPRSA-N Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O NFNVDJGXRFEYTK-YUMQZZPRSA-N 0.000 description 1
DZQMXBALGUHGJT-GUBZILKMSA-N Leu-Glu-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O DZQMXBALGUHGJT-GUBZILKMSA-N 0.000 description 1
LESXFEZIFXFIQR-LURJTMIESA-N Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(O)=O LESXFEZIFXFIQR-LURJTMIESA-N 0.000 description 1
OXRLYTYUXAQTHP-YUMQZZPRSA-N Leu-Gly-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(O)=O OXRLYTYUXAQTHP-YUMQZZPRSA-N 0.000 description 1
RXGLHDWAZQECBI-SRVKXCTJSA-N Leu-Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O RXGLHDWAZQECBI-SRVKXCTJSA-N 0.000 description 1
XWEVVRRSIOBJOO-SRVKXCTJSA-N Leu-Pro-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O XWEVVRRSIOBJOO-SRVKXCTJSA-N 0.000 description 1
UCBPDSYUVAAHCD-UWVGGRQHSA-N Leu-Pro-Gly Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UCBPDSYUVAAHCD-UWVGGRQHSA-N 0.000 description 1
JIHDFWWRYHSAQB-GUBZILKMSA-N Leu-Ser-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O JIHDFWWRYHSAQB-GUBZILKMSA-N 0.000 description 1
XOWMDXHFSBCAKQ-SRVKXCTJSA-N Leu-Ser-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(C)C XOWMDXHFSBCAKQ-SRVKXCTJSA-N 0.000 description 1
GZRABTMNWJXFMH-UVOCVTCTSA-N Leu-Thr-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZRABTMNWJXFMH-UVOCVTCTSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
FSNCEEGOMTYXKY-JTQLQIEISA-N Lycoperodine 1 Natural products N1C2=CC=CC=C2C2=C1CN[C@H](C(=O)O)C2 FSNCEEGOMTYXKY-JTQLQIEISA-N 0.000 description 1
VUTWYNQUSJWBHO-BZSNNMDCSA-N Lys-Leu-Tyr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O VUTWYNQUSJWBHO-BZSNNMDCSA-N 0.000 description 1
NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
ADHNYKZHPOEULM-BQBZGAKWSA-N Met-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O ADHNYKZHPOEULM-BQBZGAKWSA-N 0.000 description 1
QXOHLNCNYLGICT-YFKPBYRVSA-N Met-Gly Chemical compound CSCC[C@H](N)C(=O)NCC(O)=O QXOHLNCNYLGICT-YFKPBYRVSA-N 0.000 description 1
UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
108010086093 Mung Bean Nuclease Proteins 0.000 description 1
WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 1
SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
102000005348 Neuraminidase Human genes 0.000 description 1
108010006232 Neuraminidase Proteins 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
230000004989 O-glycosylation Effects 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
QTDBZORPVYTRJU-KKXDTOCCSA-N Phe-Tyr-Ala Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O QTDBZORPVYTRJU-KKXDTOCCSA-N 0.000 description 1
FELJDCNGZFDUNR-WDSKDSINSA-N Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 FELJDCNGZFDUNR-WDSKDSINSA-N 0.000 description 1
YXHYJEPDKSYPSQ-AVGNSLFASA-N Pro-Leu-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 YXHYJEPDKSYPSQ-AVGNSLFASA-N 0.000 description 1
FXGIMYRVJJEIIM-UWVGGRQHSA-N Pro-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 FXGIMYRVJJEIIM-UWVGGRQHSA-N 0.000 description 1
JLMZKEQFMVORMA-SRVKXCTJSA-N Pro-Pro-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 JLMZKEQFMVORMA-SRVKXCTJSA-N 0.000 description 1
LNICFEXCAHIJOR-DCAQKATOSA-N Pro-Ser-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O LNICFEXCAHIJOR-DCAQKATOSA-N 0.000 description 1
SNGZLPOXVRTNMB-LPEHRKFASA-N Pro-Ser-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CO)C(=O)N2CCC[C@@H]2C(=O)O SNGZLPOXVRTNMB-LPEHRKFASA-N 0.000 description 1
101100175800 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GLN3 gene Proteins 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
ZUGXSSFMTXKHJS-ZLUOBGJFSA-N Ser-Ala-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O ZUGXSSFMTXKHJS-ZLUOBGJFSA-N 0.000 description 1
RZEQTVHJZCIUBT-WDSKDSINSA-N Ser-Arg Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N RZEQTVHJZCIUBT-WDSKDSINSA-N 0.000 description 1
KCGIREHVWRXNDH-GARJFASQSA-N Ser-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N KCGIREHVWRXNDH-GARJFASQSA-N 0.000 description 1
JURQXQBJKUHGJS-UHFFFAOYSA-N Ser-Ser-Ser-Ser Chemical compound OCC(N)C(=O)NC(CO)C(=O)NC(CO)C(=O)NC(CO)C(O)=O JURQXQBJKUHGJS-UHFFFAOYSA-N 0.000 description 1
VPZKQTYZIVOJDV-LMVFSUKVSA-N Thr-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(O)=O VPZKQTYZIVOJDV-LMVFSUKVSA-N 0.000 description 1
IQHUITKNHOKGFC-MIMYLULJSA-N Thr-Phe Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IQHUITKNHOKGFC-MIMYLULJSA-N 0.000 description 1
VTMGKRABARCZAX-OSUNSFLBSA-N Thr-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)[C@@H](C)O VTMGKRABARCZAX-OSUNSFLBSA-N 0.000 description 1
WPSYJHFHZYJXMW-JSGCOSHPSA-N Trp-Gln-Gly Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O WPSYJHFHZYJXMW-JSGCOSHPSA-N 0.000 description 1
YTZYHKOSHOXTHA-TUSQITKMSA-N Trp-Leu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CC=3C4=CC=CC=C4NC=3)CC(C)C)C(O)=O)=CNC2=C1 YTZYHKOSHOXTHA-TUSQITKMSA-N 0.000 description 1
ZHZLQVLQBDBQCQ-WDSOQIARSA-N Trp-Lys-Arg Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N ZHZLQVLQBDBQCQ-WDSOQIARSA-N 0.000 description 1
ZSXJENBJGRHKIG-UWVGGRQHSA-N Tyr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 ZSXJENBJGRHKIG-UWVGGRQHSA-N 0.000 description 1
PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
208000021841 acute erythroid leukemia Diseases 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
239000000959 ampholyte mixture Substances 0.000 description 1
238000005349 anion exchange Methods 0.000 description 1
238000005571 anion exchange chromatography Methods 0.000 description 1
239000003957 anion exchange resin Substances 0.000 description 1
238000000137 annealing Methods 0.000 description 1
108010027485 asialoerythropoietin Proteins 0.000 description 1
239000012131 assay buffer Substances 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
108010057005 beta-galactoside alpha-2,3-sialyltransferase Proteins 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
238000009835 boiling Methods 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
238000012511 carbohydrate analysis Methods 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
238000011109 contamination Methods 0.000 description 1
NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
239000006167 equilibration buffer Substances 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000012997 ficoll-paque Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
108010049041 glutamylalanine Proteins 0.000 description 1
230000001279 glycosylating effect Effects 0.000 description 1
VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
108010050848 glycylleucine Proteins 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
108010057760 hepatic sialoglycoprotein receptor Proteins 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
229910052588 hydroxylapatite Inorganic materials 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
239000012133 immunoprecipitate Substances 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000035800 maturation Effects 0.000 description 1
108010056582 methionylglutamic acid Proteins 0.000 description 1
108010005942 methionylglycine Proteins 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
239000006916 nutrient agar Substances 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
239000006174 pH buffer Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
238000002732 pharmacokinetic assay Methods 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
230000036515 potency Effects 0.000 description 1
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
239000013014 purified material Substances 0.000 description 1
239000008213 purified water Substances 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000000611 regression analysis Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
210000001995 reticulocyte Anatomy 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
238000002791 soaking Methods 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
230000004960 subcellular localization Effects 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
108010061238 threonyl-glycine Proteins 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
108010080629 tryptophan-leucine Proteins 0.000 description 1
125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Hematology (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)
Medicines Containing Plant Substances (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

LVP-95-99A 1993-08-17 1995-04-17 Erythropoietin analogs LV10972B (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10801693A	1993-08-17	1993-08-17
PCT/US1994/009257 WO1995005465A1 (en)	1993-08-17	1994-08-16	Erythropoietin analogs

Publications (2)

Publication Number	Publication Date
LV10972A LV10972A (lv)	1995-12-20
LV10972B true LV10972B (en)	1996-10-20

Family

ID=22319789

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LVP-95-99A LV10972B (en)	1993-08-17	1995-04-17	Erythropoietin analogs

Country Status (27)

Country	Link
EP (1)	EP0640619B2 (no)
JP (3)	JP2938572B2 (no)
KR (2)	KR100328769B1 (no)
CN (1)	CN1057534C (no)
AT (1)	ATE155796T1 (no)
AU (1)	AU677097B2 (no)
CA (1)	CA2147124C (no)
CZ (3)	CZ291229B6 (no)
DE (2)	DE69404401T3 (no)
DK (1)	DK0640619T4 (no)
ES (1)	ES2105442T5 (no)
FI (1)	FI117136B (no)
GR (1)	GR3024815T3 (no)
HK (1)	HK1001589A1 (no)
HU (1)	HU220334B (no)
IL (4)	IL110669A (no)
LU (1)	LU90850I2 (no)
LV (1)	LV10972B (no)
NL (1)	NL300075I2 (no)
NO (2)	NO323104B1 (no)
NZ (1)	NZ273134A (no)
RU (1)	RU2159814C2 (no)
SI (1)	SI0640619T2 (no)
SK (1)	SK282003B6 (no)
UA (1)	UA49793C2 (no)
WO (1)	WO1995005465A1 (no)
ZA (1)	ZA946122B (no)

Families Citing this family (242)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7217689B1 (en)	1989-10-13	2007-05-15	Amgen Inc.	Glycosylation analogs of erythropoietin
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5614184A (en)	1992-07-28	1997-03-25	New England Deaconess Hospital	Recombinant human erythropoietin mutants and therapeutic methods employing them
US5696250A (en) *	1995-02-15	1997-12-09	Amgen Inc.	DNA encoding megakaryocyte growth and development factor analogs
US5989538A (en) *	1995-02-15	1999-11-23	Amgen Inc.	Mpl ligand analogs
EP0854882A1 (en) *	1995-10-09	1998-07-29	PHARMACIA & UPJOHN COMPANY	An acceptor polypeptide for an n-acetylgalactosaminyltransferase
KR100400637B1 (ko) *	1996-02-06	2004-03-10	씨제이 주식회사	생물학적으로유용한펩타이드
US6504007B1 (en)	1996-03-14	2003-01-07	Genentech, Inc.	GDNF receptor
US5952226A (en) *	1996-11-05	1999-09-14	Modex Therapeutiques	Hypoxia responsive EPO producing cells
ATE255634T1 (de) *	1997-09-01	2003-12-15	Aventis Pharma Gmbh	Rekombinantes humanes erythropoietin mit vorteilhaftem glykosylierungsmuster
DK1037927T3 (da)	1997-12-08	2004-09-06	Emd Lexigen Res Ct Corp	Heterodimere fusionsproteiner, der er nyttige til målrettet immunterapi og generel immunstimulering
EP1088084B1 (en)	1998-06-15	2006-09-13	GTC Biotherapeutics, Inc.	Erythropoietin analog-human serum albumin fusion protein
US7304150B1 (en)	1998-10-23	2007-12-04	Amgen Inc.	Methods and compositions for the prevention and treatment of anemia
CN101703760A (zh) *	1998-10-23	2010-05-12	安姆根有限公司	用于预防和治疗贫血的方法以及组合物
DE19857609A1 (de)	1998-12-14	2000-06-15	Hannelore Ehrenreich	Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
PT1151102E (pt) *	1999-02-12	2006-07-31	Amgen Inc	Composicoes de leptina glicosilada e metodos afins
US7345019B1 (en)	1999-04-13	2008-03-18	The Kenneth S. Warren Institute, Inc.	Modulation of excitable tissue function by peripherally administered erythropoietin
US7410941B1 (en)	1999-04-13	2008-08-12	The Kenneth S. Warren Institute, Inc.	Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin
US8236561B2 (en)	1999-04-15	2012-08-07	Crucell Holland B.V.	Efficient production of IgA in recombinant mammalian cells
US7604960B2 (en)	1999-04-15	2009-10-20	Crucell Holland B.V.	Transient protein expression methods
US6855544B1 (en)	1999-04-15	2005-02-15	Crucell Holland B.V.	Recombinant protein production in a human cell
US7297680B2 (en)	1999-04-15	2007-11-20	Crucell Holland B.V.	Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
JP3660880B2 (ja) *	1999-05-07	2005-06-15	ジェネンテック・インコーポレーテッド	新規なチンパンジーエリスロポエチン（ｃｈｅｐｏ）ポリペプチドおよびこれをコードする核酸
US6555343B1 (en)	1999-05-07	2003-04-29	Genentech Inc.	Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
US6831060B2 (en)	1999-05-07	2004-12-14	Genentech, Inc.	Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
CZ299516B6 (cs) *	1999-07-02	2008-08-20	F. Hoffmann-La Roche Ag	Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
PE20010288A1 (es) *	1999-07-02	2001-03-07	Hoffmann La Roche	Derivados de eritropoyetina
SK782002A3 (en)	1999-07-21	2003-08-05	Lexigen Pharm Corp	FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en)	1999-07-21	2006-06-27	Emd Lexigen Research Center Corp.	Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
RU2263118C2 (ru)	1999-08-09	2005-10-27	Лексиген Фармасьютикэлс Корп.	Комплексы антител с несколькими цитокинами
JP2003514552A (ja) *	1999-11-12	2003-04-22	メルクパテントゲゼルシャフトミットベシュレンクテルハフトング	改善された性質を有するエリトロポエチンの形態
US7527961B2 (en)	1999-11-26	2009-05-05	Crucell Holland B.V.	Production of vaccines
US7192759B1 (en)	1999-11-26	2007-03-20	Crucell Holland B.V.	Production of vaccines
US7521220B2 (en)	1999-11-26	2009-04-21	Crucell Holland B.V.	Production of vaccines
CA2399832C (en)	2000-02-11	2011-09-20	Stephen D. Gillies	Enhancing the circulating half-life of antibody-based fusion proteins
US6586398B1 (en) *	2000-04-07	2003-07-01	Amgen, Inc.	Chemically modified novel erythropoietin stimulating protein compositions and methods
CA2405709A1 (en)	2000-04-12	2001-10-25	Human Genome Sciences, Inc.	Albumin fusion proteins
JP5022551B2 (ja) *	2000-04-21	2012-09-12	アムジエン・インコーポレーテツド	貧血の予防及び治療用の方法及び組成物
PT1311285E (pt) *	2000-05-15	2005-06-30	Hoffmann La Roche	Composicao farmaceutica liquida contendo um derivado de eritropoietina
US7259146B2 (en)	2000-05-26	2007-08-21	Ortho-Mcneil Pharmaceutical, Inc.	Neuroprotective peptides
CA2412845C (en)	2000-06-29	2014-07-22	Lexigen Pharmaceuticals Corp.	Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
EP1336410A4 (en)	2000-08-04	2005-10-12	Chugai Pharmaceutical Co Ltd	PROTEIN INJECTION PREPARATIONS
DK1314437T3 (da)	2000-08-11	2014-07-14	Chugai Pharmaceutical Co Ltd	Stabiliserede antistofindeholdende præparater
KR101229995B1 (ko)	2000-12-11	2013-02-06	씨제이 주식회사	생체내 에리스로포이에틴 활성이 증진된 융합단백질
AU2002222740A1 (en) *	2000-12-11	2002-06-24	Cheil Jedang Corporation	Fusion protein having the enhanced in vivo activity of erythropoietin
BR0116381A (pt) *	2000-12-20	2004-02-25	Hoffmann La Roche	Conjugado, composição farmacêutica que compreende o mesmo e sua utilização, processo para o tratamento profilático e/ou terapêutico de distúrbios, processo para a preparação de um conjugado, compostos e glicoproteìnas de eritropoetina
PA8536201A1 (es)	2000-12-29	2002-08-29	Kenneth S Warren Inst Inc	Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
US20030072737A1 (en)	2000-12-29	2003-04-17	Michael Brines	Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US6531121B2 (en)	2000-12-29	2003-03-11	The Kenneth S. Warren Institute, Inc.	Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US7767643B2 (en)	2000-12-29	2010-08-03	The Kenneth S. Warren Institute, Inc.	Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
DE60219961T8 (de)	2001-02-02	2008-04-17	Ortho-Mcneil Pharmaceutical, Inc.	Behandlung von neurologischen funktionsstörungen mit fructopyranosesulfamaten und erythropoetin
PL206701B1 (pl)	2001-03-07	2010-09-30	Merck Patent Gmbh	Immunoglobulinowe białko fuzyjne, kodujący je kwas nukleinowy, replikujący wektor ekspresji zawierający taki kwas nukleinowy, eukariotyczna komórka gospodarza zawierająca taki wektor ekspresji oraz sposób zwiększania ekspresji takiego białka fuzyjnego
ES2869895T3 (es)	2001-03-09	2021-10-26	Chugai Pharmaceutical Co Ltd	Método de purificación de proteínas
DE10112825A1 (de)	2001-03-16	2002-10-02	Fresenius Kabi De Gmbh	HESylierung von Wirkstoffen in wässriger Lösung
US6992174B2 (en)	2001-03-30	2006-01-31	Emd Lexigen Research Center Corp.	Reducing the immunogenicity of fusion proteins
FR2823220B1 (fr) *	2001-04-04	2003-12-12	Genodyssee	Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
EP2975382B1 (en)	2001-04-17	2017-12-27	Chugai Seiyaku Kabushiki Kaisha	Method of quantifying surfactant
WO2002090566A2 (en)	2001-05-03	2002-11-14	Merck Patent Gmbh	Recombinant tumor specific antibody and use thereof
US6930086B2 (en)	2001-09-25	2005-08-16	Hoffmann-La Roche Inc.	Diglycosylated erythropoietin
US7173003B2 (en)	2001-10-10	2007-02-06	Neose Technologies, Inc.	Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
WO2004099231A2 (en)	2003-04-09	2004-11-18	Neose Technologies, Inc.	Glycopegylation methods and proteins/peptides produced by the methods
US7214660B2 (en) *	2001-10-10	2007-05-08	Neose Technologies, Inc.	Erythropoietin: remodeling and glycoconjugation of erythropoietin
US6818613B2 (en)	2001-11-07	2004-11-16	Ortho-Mcneil Pharmaceutical, Inc.	Aqueous sustained-release formulations of proteins
US7232797B2 (en)	2001-11-28	2007-06-19	Ortho-Mcneil Pharmaceutical, Inc.	Erythropoietin dosing regimen for treating anemia
KR100467750B1 (ko) *	2001-11-29	2005-01-24	씨제이 주식회사	생체내 에리스로포이에틴 활성이 증진된 융합단백질
KR100467751B1 (ko) *	2001-12-03	2005-01-24	씨제이 주식회사	생체내 에리스로포이에틴 활성이 증진된 융합단백질
CA2469151C (en)	2001-12-04	2013-08-13	Merck Patent Gesellschaft Mit Beschraenkter Haftung	Immunocytokines with modulated selectivity
CN100547069C (zh)	2001-12-07	2009-10-07	克鲁塞尔荷兰公司	病毒、病毒分离物和疫苗的生产
ES2545090T3 (es)	2001-12-21	2015-09-08	Human Genome Sciences, Inc.	Proteínas de fusión de albúmina y GCSF
WO2005003296A2 (en)	2003-01-22	2005-01-13	Human Genome Sciences, Inc.	Albumin fusion proteins
DE10209822A1 (de)	2002-03-06	2003-09-25	Biotechnologie Ges Mittelhesse	Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
DE10209821A1 (de)	2002-03-06	2003-09-25	Biotechnologie Ges Mittelhesse	Kopplung von Proteinen an ein modifiziertes Polysaccharid
US7129267B2 (en)	2002-03-11	2006-10-31	Janssen Pharmaceutica N.V.	Methods for SHP1 mediated neuroprotection
US20030191056A1 (en)	2002-04-04	2003-10-09	Kenneth Walker	Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
NZ537306A (en) *	2002-07-01	2008-11-28	Kenneth S Warren Inst Inc	Compositions comprising mutein recombinant tissue protective cytokines having one or more amino acid substitutions facilitating transport of a molecule via transcytosis across an endothelial cell barrier
WO2004009627A1 (en) *	2002-07-19	2004-01-29	Cangene Corporation	Pegylated erythropoietic compounds
DE10234192B4 (de)	2002-07-26	2009-11-26	Epoplus Gmbh Co.Kg	Verwendung von Erythropoetin
WO2004019966A1 (ja)	2002-08-27	2004-03-11	Chugai Seiyaku Kabushiki Kaisha	タンパク質溶液製剤の安定化方法
US7459435B2 (en)	2002-08-29	2008-12-02	Hoffmann-La Roche Inc.	Treatment of disturbances of iron distribution
AU2003263552A1 (en)	2002-09-09	2004-03-29	Nautilus Biotech	Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
IL166506A0 (en)	2002-09-11	2006-01-15	Fresenius Kabi De Gmbh	Hasylated polypeptides especially hasylated erythropoietin
EP2261230B1 (en)	2002-09-11	2017-05-10	Chugai Seiyaku Kabushiki Kaisha	Protein purification method
DE20321793U1 (de)	2002-09-11	2010-06-02	Fresenius Kabi Deutschland Gmbh	Hydroxyalkylstärke-Derivate
EP1681303B1 (en)	2002-09-11	2013-09-04	Fresenius Kabi Deutschland GmbH	HASylated polypeptides, especially HASylated erythropoietin
ES2314238T3 (es)	2002-10-08	2009-03-16	Fresenius Kabi Deutschland Gmbh	Conjugados de oligosacaridos farmaceuticamente activos.
EP1551987A1 (en) *	2002-10-17	2005-07-13	Pharming Intellectual Property B.V.	Protein modification
US7459436B2 (en)	2002-11-22	2008-12-02	Hoffmann-La Roche Inc.	Treatment of disturbances of iron distribution
PT1572748E (pt)	2002-12-17	2010-09-28	Merck Patent Gmbh	Anticorpo humanizado (h14.18) do anticorpo 14.18 de rato que se liga ao gd2 e a sua fusão com a il-2
KR101183770B1 (ko)	2003-05-09	2012-09-17	크루셀 홀란드 비.브이.	Ｅ1-불멸화된 세포의 배양물 및 이로부터 생성 수율을 증가시키기 위한 동일물의 배양 방법
WO2005012484A2 (en)	2003-07-25	2005-02-10	Neose Technologies, Inc.	Antibody-toxin conjugates
WO2005014655A2 (en)	2003-08-08	2005-02-17	Fresenius Kabi Deutschland Gmbh	Conjugates of hydroxyalkyl starch and a protein
ZA200603396B (en)	2003-09-29	2007-11-28	Warren Pharmaceuticals Inc	Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
US20080305992A1 (en)	2003-11-24	2008-12-11	Neose Technologies, Inc.	Glycopegylated erythropoietin
ES2346226T3 (es)	2003-12-30	2010-10-13	Augustinus Bader	Uso de la eritropoyetina para la regeneracion de tejido hepatico.
DK1699821T3 (da)	2003-12-31	2012-07-16	Merck Patent Gmbh	Fc-ERYTHROPOIETIN-FUSIONSPROTEIN MED FORBEDREDE FARMAKOKINETIKKER
DE102004063927A1 (de)	2004-01-23	2005-12-15	Epoplus Gmbh Co.Kg	Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
KR101186821B1 (ko)	2004-03-11	2012-09-28	프레제니우스 카비 도이치란트 게엠베하	환원성 아미노화에 의해 제조된, 하이드록시알킬 녹말 및단백질의 접합체
US20080300173A1 (en)	2004-07-13	2008-12-04	Defrees Shawn	Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
US7597884B2 (en)	2004-08-09	2009-10-06	Alios Biopharma, Inc.	Hyperglycosylated polypeptide variants and methods of use
CA2585758C (en)	2004-10-29	2017-08-01	Neose Technologies, Inc.	Remodeling and glycopegylation of fibroblast growth factor (fgf)
NZ556436A (en)	2005-01-10	2010-11-26	Biogenerix Ag	Glycopegylated granulocyte colony stimulating factor
WO2006121569A2 (en)	2005-04-08	2006-11-16	Neose Technologies, Inc.	Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US9988427B2 (en)	2005-05-13	2018-06-05	Charite Universitaetsmedizen-Berlin	Erythropoietin variants
EP1736481A1 (en)	2005-05-13	2006-12-27	Charite Universitätsmedizin-Berlin	Erythropoietin variants
US20070105755A1 (en)	2005-10-26	2007-05-10	Neose Technologies, Inc.	One pot desialylation and glycopegylation of therapeutic peptides
CN100432107C (zh) *	2005-10-25	2008-11-12	北京大学	具有促红细胞生长因子活性的蛋白质及其用途
WO2007056191A2 (en)	2005-11-03	2007-05-18	Neose Technologies, Inc.	Nucleotide sugar purification using membranes
WO2007067564A2 (en)	2005-12-08	2007-06-14	Amgen Inc.	Improved host cells and culture methods
SI1957630T2 (sl)	2005-12-08	2023-07-31	Amgen Inc.	Izboljšana proizvodnja glikoproteinov z uporabo mangana
DE102006004008A1 (de)	2006-01-27	2007-08-02	Hannelore Prof. Dr. Dr. Ehrenreich	Verfahren zur Behandlung und/oder Prophylaxe von Multipler Sklerose, sowie Verwendung von Erythropoietin zur Herstellung eines Arzneimittels zur intermittierenden Behandlung und/oder intermittierenden Prophylaxe von Multipler Sklerose
WO2007108505A1 (ja)	2006-03-22	2007-09-27	Chugai Seiyaku Kabushiki Kaisha	エリスロポエチン溶液製剤
CN101062407A (zh)	2006-04-29	2007-10-31	中国科学院上海生命科学研究院	促红细胞生成素在预防或治疗视网膜损伤中的用途
CN103255162A (zh)	2006-05-19	2013-08-21	格利科菲公司	促红细胞生成素组合物
MX2009000685A (es)	2006-07-21	2009-01-30	Amgen Inc	Metodo para detectar y/o cuantificar hepcidina en una muestra.
CN101516388B (zh)	2006-07-21	2012-10-31	诺和诺德公司	通过o-联糖基化序列的肽的糖基化
EP2057997A4 (en)	2006-08-22	2012-11-07	Chugai Pharmaceutical Co Ltd	MEANS FOR THE PREVENTION AND / OR TREATMENT OF PERIPHERAL NEUROPATHY
US8969532B2 (en)	2006-10-03	2015-03-03	Novo Nordisk A/S	Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
CN101337988B (zh) *	2006-10-31	2013-01-09	沈阳三生制药有限责任公司	一种新的促红细胞生成素类似物
EP2081956B1 (en)	2006-11-13	2013-03-20	Charité - Universitätsmedizin Berlin	Method of cell culture and method of treatment comprising a vepo protein variant
EP2120998B1 (en)	2006-11-28	2013-08-07	HanAll Biopharma Co., Ltd.	Modified erythropoietin polypeptides and uses thereof for treatment
AR065613A1 (es)	2007-03-09	2009-06-17	Chugai Pharmaceutical Co Ltd	Agentes de proteccion para organos transplantados
NZ580030A (en)	2007-04-03	2012-06-29	Biogenerix Ag	Methods of treatment using glycopegylated g-csf
WO2008154639A2 (en)	2007-06-12	2008-12-18	Neose Technologies, Inc.	Improved process for the production of nucleotide sugars
US20100172919A1 (en) *	2007-06-15	2010-07-08	Jan Grimm	Noveltreatment for neurological disorders
CN103113464B (zh) *	2007-07-02	2014-08-20	沈阳三生制药有限责任公司	天然人促红细胞生成素类似物
CN103073631A (zh) *	2007-07-02	2013-05-01	沈阳三生制药有限责任公司	一种促红细胞生成素类似物
WO2009010107A1 (en)	2007-07-19	2009-01-22	Hannelore Ehrenreich	Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis
AU2008304111B2 (en)	2007-09-27	2014-04-24	Amgen Inc.	Pharmaceutical formulations
US8796206B2 (en)	2007-11-15	2014-08-05	Amgen Inc.	Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
EP2070950A1 (en)	2007-12-14	2009-06-17	Fresenius Kabi Deutschland GmbH	Hydroxyalkyl starch derivatives and process for their preparation
CA2711826C (en)	2008-01-25	2018-02-27	Amgen Inc.	Ferroportin antibodies and methods of use
US9938333B2 (en)	2008-02-08	2018-04-10	Ambrx, Inc.	Modified leptin polypeptides and their uses
EP2095829A1 (en)	2008-02-27	2009-09-02	LEK Pharmaceuticals D.D.	Selenium containing modifying agents and conjugates
EP2626079A3 (en)	2008-02-27	2014-03-05	Novo Nordisk A/S	Conjungated factor VIII molecules
WO2009130198A2 (en)	2008-04-21	2009-10-29	Novo Nordisk A/S	Hyperglycosylated human coagulation factor ix
EP2294087B1 (en)	2008-05-01	2014-05-14	Amgen, Inc.	Anti-hepcidin antibodies and methods of use
JP5632376B2 (ja)	2008-09-23	2014-11-26	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	エリスロポエチンの精製
NZ601659A (en)	2008-09-26	2014-02-28	Ambrx Inc	Modified animal erythropoietin polypeptides and their uses
WO2010056981A2 (en)	2008-11-13	2010-05-20	Massachusetts General Hospital	Methods and compositions for regulating iron homeostasis by modulation bmp-6
CA2748932C (en) *	2009-02-19	2019-11-19	Martin Mansson	Process for purifying lipopeptides
US20100272816A1 (en)	2009-04-27	2010-10-28	Wolfgang Rudinger	Microcapsules comprising liver cells and erythropoietin, methods for preparing said microcapsules and methods for treating a patient comprising applying said microcapsules to the patient
EP3009447B1 (en)	2009-07-24	2018-06-06	Dr. Reddy's Laboratories, Ltd.	Production of erythropoiesis stimulating protein using metal ions
WO2011024025A1 (en) *	2009-08-28	2011-03-03	Avesthagen Limited	An erythropoietin analogue and a method thereof
CA2778105C (en)	2009-10-23	2019-04-02	Amgen Inc.	Vial adapter and system
JP5981423B2 (ja)	2010-06-07	2016-08-31	アムジエン・インコーポレーテツド	薬物送達デバイス
US8193296B2 (en)	2010-06-30	2012-06-05	Nike, Inc.	Golf balls including crosslinked thermoplastic polyurethane
US20120115637A1 (en)	2010-06-30	2012-05-10	Nike, Inc.	Golf Balls Including A Crosslinked Thermoplastic Polyurethane Cover Layer Having Improved Scuff Resistance
RU2451071C1 (ru) *	2010-12-10	2012-05-20	Российская Федерация, от имени которой выступает Министерство образования и науки Российской Федерации (Минобрнауки России)	Штамм гибридных культивируемых клеток животных mus musculus - продуцент моноклональных антител к рекомбинантному эритропоэтину человека (варианты)
US9480624B2 (en)	2011-03-31	2016-11-01	Amgen Inc.	Vial adapter and system
EP4074355A1 (en)	2011-04-20	2022-10-19	Amgen Inc.	Autoinjector apparatus
US8979676B2 (en)	2011-08-23	2015-03-17	Nike, Inc.	Multi-core golf ball having increased initial velocity at high swing speeds relative to low swing speeds
US9089739B2 (en)	2011-08-23	2015-07-28	Nike, Inc.	Multi-core golf ball having increased initial velocity
EP3045190B1 (en)	2011-10-14	2022-06-15	Amgen Inc.	Injector and method of assembly
KR101443257B1 (ko) *	2011-10-18	2014-09-19	주식회사 종근당	낮은 등전점을 갖는 에리스로포이에틴 유사체의 정제방법
CN102788720B (zh) *	2012-06-05	2016-01-06	西北大学	一种滤膜辅助分离生物样本中糖蛋白全n-连接糖链及其鉴别方法
CA3206182A1 (en)	2012-11-21	2014-05-30	Amgen Inc.	Drug delivery device including insertion member and reservoir
CN103864913A (zh)	2012-12-18	2014-06-18	联亚生技开发股份有限公司	重组蛋白
WO2014144096A1 (en)	2013-03-15	2014-09-18	Amgen Inc.	Drug cassette, autoinjector, and autoinjector system
SG11201507417RA (en)	2013-03-15	2015-10-29	Amgen Inc	Body contour adaptable autoinjector device
US9657098B2 (en)	2013-03-15	2017-05-23	Intrinsic Lifesciences, Llc	Anti-hepcidin antibodies and uses thereof
TWI639453B (zh)	2013-03-15	2018-11-01	美商安美基公司	用於注射器之匣盒
SG11201507878SA (en)	2013-03-22	2015-10-29	Amgen Inc	Injector and method of assembly
EP3421066B1 (en)	2013-10-24	2021-03-03	Amgen Inc.	Injector and method of assembly
MX2016005315A (es)	2013-10-24	2016-08-11	Amgen Inc	Sistema de administracion de farmacos con control sensible a la temperatura.
KR101414897B1 (ko)	2013-11-29	2014-07-04	씨제이헬스케어 주식회사	다베포에틴 알파의 정제 방법
WO2015119906A1 (en)	2014-02-05	2015-08-13	Amgen Inc.	Drug delivery system with electromagnetic field generator
AU2015256082C1 (en)	2014-05-07	2020-09-10	Amgen Inc.	Autoinjector with shock reducing elements
SG11201609963PA (en)	2014-06-03	2016-12-29	Amgen Inc	Devices and methods for assisting a user of a drug delivery device
EP3194429A4 (en) *	2014-09-18	2018-06-13	Askgene Pharma, Inc.	Novel feline erythropoietin receptor agonists
CA2961917A1 (en)	2014-09-22	2016-03-31	Intrinsic Lifesciences Llc	Humanized anti-hepcidin antibodies and uses thereof
EP3943135A3 (en)	2014-10-14	2022-06-29	Amgen Inc.	Drug injection device with visual and audible indicators
EP3233163B1 (en)	2014-12-19	2021-10-13	Amgen Inc.	Drug delivery device with proximity sensor
US11357916B2 (en)	2014-12-19	2022-06-14	Amgen Inc.	Drug delivery device with live button or user interface field
ES2748750T3 (es)	2015-02-17	2020-03-17	Amgen Inc	Dispositivo de administración de fármacos con sujeción asistida por vacío y/o realimentación
EP3981450A1 (en)	2015-02-27	2022-04-13	Amgen, Inc	Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
WO2017039786A1 (en)	2015-09-02	2017-03-09	Amgen Inc.	Syringe assembly adapter for a syringe
ES2755717T3 (es)	2015-12-09	2020-04-23	Amgen Inc	Autoinyector con tapa de señalización
US11154661B2 (en)	2016-01-06	2021-10-26	Amgen Inc.	Auto-injector with signaling electronics
EP3428284B1 (en) *	2016-03-09	2022-05-11	JCR Pharmaceuticals CO., LTD.	Method for producing mutant human erythropoietin
WO2017160799A1 (en)	2016-03-15	2017-09-21	Amgen Inc.	Reducing probability of glass breakage in drug delivery devices
WO2017189089A1 (en)	2016-04-29	2017-11-02	Amgen Inc.	Drug delivery device with messaging label
US11389588B2 (en)	2016-05-02	2022-07-19	Amgen Inc.	Syringe adapter and guide for filling an on-body injector
WO2017197222A1 (en)	2016-05-13	2017-11-16	Amgen Inc.	Vial sleeve assembly
EP3458988B1 (en)	2016-05-16	2023-10-18	Amgen Inc.	Data encryption in medical devices with limited computational capability
GB2550418A (en)	2016-05-20	2017-11-22	Laing Peter	An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies
EP3465124A1 (en)	2016-06-03	2019-04-10	Amgen Inc.	Impact testing apparatuses and methods for drug delivery devices
US11285266B2 (en)	2016-07-01	2022-03-29	Amgen Inc.	Drug delivery device having minimized risk of component fracture upon impact events
WO2018034784A1 (en)	2016-08-17	2018-02-22	Amgen Inc.	Drug delivery device with placement detection
WO2018081234A1 (en)	2016-10-25	2018-05-03	Amgen Inc.	On-body injector
WO2018136398A1 (en)	2017-01-17	2018-07-26	Amgen Inc.	Injection devices and related methods of use and assembly
JP7280189B2 (ja)	2017-02-17	2023-05-23	アムジエン・インコーポレーテツド	薬物送達装置用の挿入機構
JP7064501B2 (ja)	2017-02-17	2022-05-10	アムジエン・インコーポレーテツド	無菌流体流路を備える薬物送達デバイスおよび関連する組立方法
JP6258536B1 (ja) *	2017-03-03	2018-01-10	協和発酵キリン株式会社	ダルベポエチン組成物の製造方法およびダルべポエチン産生細胞の培養方法
EP3592403A1 (en)	2017-03-06	2020-01-15	Amgen Inc.	Drug delivery device with activation prevention feature
WO2018164829A1 (en)	2017-03-07	2018-09-13	Amgen Inc.	Needle insertion by overpressure
IL303449B2 (en)	2017-03-09	2024-08-01	Amgen Inc	Insertion mechanism for a drug delivery device
JP2020511499A (ja)	2017-03-20	2020-04-16	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	赤血球生成刺激タンパク質のインビトロでの糖鎖改変のための方法
ES2959935T3 (es)	2017-03-28	2024-02-29	Amgen Inc	Sistema y método de vástago de émbolo y conjunto de jeringa
CA3065540A1 (en)	2017-06-06	2018-12-13	Kindred Biosciences, Inc.	Erythropoietin and analogs for veterinary use
EP3634539A1 (en)	2017-06-08	2020-04-15	Amgen Inc.	Syringe assembly for a drug delivery device and method of assembly
US11904143B2 (en)	2017-06-08	2024-02-20	Amgen Inc.	Torque driven drug delivery device
EP3641857A1 (en)	2017-06-22	2020-04-29	Amgen Inc.	Device activation impact/shock reduction
WO2018237225A1 (en)	2017-06-23	2018-12-27	Amgen Inc.	Electronic drug delivery device comprising a cap activated by a switch assembly
ES2972207T3 (es)	2017-07-14	2024-06-11	Amgen Inc	Sistema de inserción-retracción de agujas con sistema de resorte de torsión doble
MA49626A (fr)	2017-07-21	2020-05-27	Amgen Inc	Élément d'étanchéité perméable aux gaz pour récipient à médicament et procédés d'assemblage
WO2019022950A1 (en)	2017-07-25	2019-01-31	Amgen Inc.	DRUG DELIVERY DEVICE WITH CONTAINER ACCESS SYSTEM AND ASSEMBLY METHOD THEREOF
US11617837B2 (en)	2017-07-25	2023-04-04	Amgen Inc.	Drug delivery device with gear module and related method of assembly
US20200164155A1 (en)	2017-08-09	2020-05-28	Amgen Inc.	Hydraulic-pneumatic pressurized chamber drug delivery system
EP3668567A1 (en)	2017-08-18	2020-06-24	Amgen Inc.	Wearable injector with sterile adhesive patch
US11103636B2 (en)	2017-08-22	2021-08-31	Amgen Inc.	Needle insertion mechanism for drug delivery device
WO2019070472A1 (en)	2017-10-04	2019-04-11	Amgen Inc.	FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE
WO2019070552A1 (en)	2017-10-06	2019-04-11	Amgen Inc.	DRUG DELIVERY DEVICE COMPRISING A LOCKOUT ASSEMBLY AND ASSOCIATED ASSEMBLY METHOD
IL273323B2 (en)	2017-10-09	2024-10-01	Amgen Inc	Drug delivery device with drive assembly and related assembly method
EP3703779A1 (en)	2017-11-03	2020-09-09	Amgen Inc.	Systems and approaches for sterilizing a drug delivery device
US20200261648A1 (en)	2017-11-06	2020-08-20	Amgen Inc.	Drug delivery device with placement and flow sensing
MA50569A (fr)	2017-11-06	2020-09-16	Amgen Inc	Ensembles de remplissage-finition et procédés associés
SG11202002966QA (en)	2017-11-10	2020-05-28	Amgen Inc	Plungers for drug delivery devices
MX2020005066A (es)	2017-11-16	2020-08-20	Amgen Inc	Autoinyector con deteccion de detencion y punto final.
JP7370969B2 (ja)	2017-11-16	2023-10-30	アムジエン・インコーポレーテツド	薬物送達デバイスの扉ラッチ機構
US10835685B2 (en)	2018-05-30	2020-11-17	Amgen Inc.	Thermal spring release mechanism for a drug delivery device
US11083840B2 (en)	2018-06-01	2021-08-10	Amgen Inc.	Modular fluid path assemblies for drug delivery devices
WO2020023336A1 (en)	2018-07-24	2020-01-30	Amgen Inc.	Hybrid drug delivery devices with grip portion
CN112351804A (zh)	2018-07-24	2021-02-09	安进公司	用于施用药物的输送装置
MA53379A (fr)	2018-07-24	2021-06-02	Amgen Inc	Dispositifs d'administration pour l'administration de médicaments
US20210260279A1 (en)	2018-07-24	2021-08-26	Amgen Inc.	Hybrid drug delivery devices with optional grip portion and related method of preparation
WO2020028009A1 (en)	2018-07-31	2020-02-06	Amgen Inc.	Fluid path assembly for a drug delivery device
JP2022500095A (ja)	2018-09-24	2022-01-04	アムジエン・インコーポレーテツド	インターベンション投薬システム及び方法
AR113091A1 (es) *	2018-09-27	2020-01-22	Univ Nacional Del Litoral	Eritropoyetina humana modificada
EP3856283A1 (en)	2018-09-28	2021-08-04	Amgen Inc.	Muscle wire escapement activation assembly for a drug delivery device
US12156991B2 (en)	2018-10-02	2024-12-03	Amgen Inc.	Injection systems for drug delivery with internal force transmission
EP3860686A1 (en)	2018-10-05	2021-08-11	Amgen Inc.	Drug delivery device having dose indicator
BR112021007016A2 (pt)	2018-10-15	2021-07-13	Amgen Inc.	dispositivo de administração de fármaco tendo mecanismo de amortecimento
TWI846741B (zh)	2018-10-15	2024-07-01	美商安進公司	用於藥物遞送裝置之平台組裝方法
TWI831847B (zh)	2018-11-01	2024-02-11	美商安進公司	部分針頭縮回之藥物遞送裝置及其操作方法
EP3873566B1 (en)	2018-11-01	2024-11-27	Amgen Inc.	Drug delivery devices with partial drug delivery member retraction
EP3873563A1 (en)	2018-11-01	2021-09-08	Amgen Inc.	Drug delivery devices with partial drug delivery member retraction
US20220160972A1 (en)	2019-04-24	2022-05-26	Amgen Inc.	Syringe sterilization verification assemblies and methods
US20220273887A1 (en)	2019-08-23	2022-09-01	Amgen Inc.	Drug delivery device with configurable needle shield engagement components and related methods
WO2022159414A1 (en)	2021-01-22	2022-07-28	University Of Rochester	Erythropoietin for gastroinfestinal dysfunction
CN117320964A (zh)	2021-05-21	2023-12-29	美国安进公司	优化药物容器的灌装方案的方法
WO2023209074A1 (en)	2022-04-28	2023-11-02	Institut National de la Santé et de la Recherche Médicale	Methods of restoring erythropoiesis in patients suffering from a sf3b1 mutant myelodysplastic syndrome by correcting coasy mis-splicing
WO2024094457A1 (en)	2022-11-02	2024-05-10	F. Hoffmann-La Roche Ag	Method for producing glycoprotein compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ210501A (en) *	1983-12-13	1991-08-27	Kirin Amgen Inc	Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4954437A (en) *	1986-09-15	1990-09-04	Integrated Genetics, Inc.	Cell encoding recombinant human erythropoietin
KR100221066B1 (ko) *	1989-10-13	1999-10-01	스튜어트 엘.왓트	에리트로포이에틴 유사체와 그를 포함하는 제약학적 조성물

1994
- 1994-08-15 IL IL110669A patent/IL110669A/en not_active IP Right Cessation
- 1994-08-15 CN CN94109128A patent/CN1057534C/zh not_active Expired - Lifetime
- 1994-08-15 ZA ZA946122A patent/ZA946122B/xx unknown
- 1994-08-15 IL IL192290A patent/IL192290A0/en unknown
- 1994-08-16 NZ NZ273134A patent/NZ273134A/en not_active IP Right Cessation
- 1994-08-16 DE DE69404401T patent/DE69404401T3/de not_active Expired - Lifetime
- 1994-08-16 UA UA95058432A patent/UA49793C2/uk unknown
- 1994-08-16 SK SK502-95A patent/SK282003B6/sk unknown
- 1994-08-16 CZ CZ1995917A patent/CZ291229B6/cs not_active IP Right Cessation
- 1994-08-16 AU AU76327/94A patent/AU677097B2/en not_active Expired
- 1994-08-16 CA CA002147124A patent/CA2147124C/en not_active Expired - Lifetime
- 1994-08-16 HU HU9501435A patent/HU220334B/hu active Protection Beyond IP Right Term
- 1994-08-16 RU RU95115239/14A patent/RU2159814C2/ru active
- 1994-08-16 EP EP94112732A patent/EP0640619B2/en not_active Expired - Lifetime
- 1994-08-16 JP JP7507153A patent/JP2938572B2/ja not_active Expired - Lifetime
- 1994-08-16 WO PCT/US1994/009257 patent/WO1995005465A1/en active IP Right Grant
- 1994-08-16 DK DK94112732T patent/DK0640619T4/da active
- 1994-08-16 AT AT94112732T patent/ATE155796T1/de active
- 1994-08-16 ES ES94112732T patent/ES2105442T5/es not_active Expired - Lifetime
- 1994-08-16 DE DE2001199059 patent/DE10199059I2/de active Active
- 1994-08-16 SI SI9430078T patent/SI0640619T2/xx unknown
- 1994-08-16 KR KR1019950701453A patent/KR100328769B1/ko not_active Expired - Lifetime
1995
- 1995-04-12 NO NO19951445A patent/NO323104B1/no not_active IP Right Cessation
- 1995-04-13 FI FI951792A patent/FI117136B/fi not_active IP Right Cessation
- 1995-04-15 KR KR1019957001453A patent/KR960701994A/ko active Pending
- 1995-04-17 LV LVP-95-99A patent/LV10972B/en unknown
1997
- 1997-09-22 GR GR970402449T patent/GR3024815T3/el unknown
1998
- 1998-01-21 HK HK98100522A patent/HK1001589A1/xx not_active IP Right Cessation
- 1998-08-24 JP JP25324498A patent/JP3664590B2/ja not_active Expired - Lifetime
2000
- 2000-05-16 IL IL13618900A patent/IL136189A0/xx unknown
- 2000-05-16 IL IL13618800A patent/IL136188A0/xx unknown
2001
- 2001-02-06 CZ CZ2001463A patent/CZ291343B6/cs not_active IP Right Cessation
- 2001-02-06 CZ CZ2001462A patent/CZ291342B6/cs not_active IP Right Cessation
- 2001-11-07 LU LU90850C patent/LU90850I2/fr unknown
- 2001-12-06 NL NL300075C patent/NL300075I2/nl unknown
2004
- 2004-06-25 JP JP2004188815A patent/JP3664723B2/ja not_active Expired - Lifetime
2007
- 2007-06-29 NO NO2007008C patent/NO2007008I2/no unknown

Also Published As

Publication number	Publication date
EP0640619A1 (en)	1995-03-01
NL300075I2 (nl)	2002-04-02
FI951792L (fi)	1995-05-18
RU2159814C2 (ru)	2000-11-27
EP0640619B1 (en)	1997-07-23
DK0640619T3 (da)	1998-02-02
HU9501435D0 (en)	1995-06-28
JP2938572B2 (ja)	1999-08-23
ES2105442T3 (es)	1997-10-16
DK0640619T4 (da)	2005-04-18
CA2147124A1 (en)	1995-02-23
GR3024815T3 (en)	1998-01-30
CZ291229B6 (cs)	2003-01-15
NL300075I1 (nl)	2002-03-01
NO323104B1 (no)	2007-01-02
ATE155796T1 (de)	1997-08-15
KR960701994A (ko)	1996-03-28
JP3664723B2 (ja)	2005-06-29
LU90850I2 (fr)	2002-01-07
CZ91795A3 (en)	1996-03-13
UA49793C2 (uk)	2002-10-15
ZA946122B (en)	1995-03-20
CA2147124C (en)	2002-11-05
DE10199059I1 (de)	2002-02-07
CZ291343B6 (cs)	2003-02-12
KR100328769B1 (ko)	2002-08-08
SK282003B6 (sk)	2001-10-08
JPH08506023A (ja)	1996-07-02
SI0640619T1 (sl)	1998-02-28
JPH11155584A (ja)	1999-06-15
RU95115239A (ru)	1997-03-27
FI117136B (fi)	2006-06-30
HU220334B (hu)	2001-12-28
DE69404401T3 (de)	2005-11-24
JP3664590B2 (ja)	2005-06-29
CN1105030A (zh)	1995-07-12
SI0640619T2 (en)	2005-06-30
FI951792A0 (fi)	1995-04-13
AU7632794A (en)	1995-03-14
IL136189A0 (en)	2001-07-24
EP0640619B2 (en)	2005-03-23
DE69404401D1 (de)	1997-09-04
HUT72849A (en)	1996-05-28
IL110669A (en)	2008-11-26
NZ273134A (en)	1997-11-24
WO1995005465A1 (en)	1995-02-23
CN1057534C (zh)	2000-10-18
SK50295A3 (en)	1995-08-09
JP2004331671A (ja)	2004-11-25
NO951445D0 (no)	1995-04-12
CZ291342B6 (cs)	2003-02-12
IL192290A0 (en)	2008-12-29
DE69404401T2 (de)	1998-02-19
NO2007008I1 (no)	2007-07-23
IL136188A0 (en)	2001-07-24
NO951445L (no)	1995-06-16
DE10199059I2 (de)	2007-11-08
ES2105442T5 (es)	2005-07-16
AU677097B2 (en)	1997-04-10
LV10972A (lv)	1995-12-20
NO2007008I2 (no)	2011-02-21
HK1001589A1 (en)	1998-06-26
IL110669A0 (en)	1994-11-11

Publication	Publication Date	Title
AU677097B2 (en)	1997-04-10	Erythropoietin analogs
US7217689B1 (en)	2007-05-15	Glycosylation analogs of erythropoietin
US5856298A (en)	1999-01-05	Erythropoietin isoforms
AU646822B2 (en)	1994-03-10	Erythropoietin isoforms
EP1228214A2 (en)	2002-08-07	Erythropoietin forms with improved properties
IE83805B1 (en)	2005-02-23	Erythropoietin analogs